Who owns Transcode Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of RNAZ from SEC Form 13F filings across 9 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 9 institutions disclosed 35,039 shares of Transcode Therapeutics, Inc. worth $217,591 — about 3.7% of shares outstanding; the largest disclosed holder is Yorkville Advisors Global, LP. Source: SEC Form 13F filings, parsed by EvidInvest.
9
13F holders
$217,591
value, 2026 filers
3.7%
of shares outstanding (35,039 sh)
3
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of RNAZ's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Yorkville Advisors Global, LPNEW | 19,639 | $121,958 | 0.1% | 2.1% | new |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 6,545 | $40,644 | 0.0% | 0.7% | 0.0% |
| 3 | VANGUARD FIDUCIARY TRUST CO | 2,982 | $18,518 | 0.0% | 0.3% | 0.0% |
| 4 | UBS Group AG | 2,888 | $17,934 | 0.0% | 0.3% | -65.2% |
| 5 | MERCER GLOBAL ADVISORS INC /ADVNEW | 1,535 | $9,532 | 0.0% | 0.2% | new |
| 6 | FMR LLCNEW | 706 | $4,384 | 0.0% | 0.1% | new |
| 7 | Tower Research Capital LLC (TRC) | 677 | $4,204 | 0.0% | 0.1% | +196.9% |
| 8 | WELLS FARGO & COMPANY/MN | 55 | $342 | 0.0% | 0% | 0.0% |
| 9 | SBI Securities Co., Ltd. | 12 | $75 | 0.0% | 0% | 0.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.